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Abstract 
 FGF/Erk MAP Kinase Signaling is a central regulator of mouse embryonic stem 
cell (mESC) self-renewal, pluripotency and differentiation. However, the mechanistic 
connection between this signaling pathway activity and the gene circuits stabilizing 
mESCs in vitro remain unclear. Here we show that FGF signaling post-transcriptionally 
regulates the mESC transcription factor network by controlling the expression of Brf1 
(zfp36l1), an AU-rich element mRNA binding protein. Changes in Brf1 level disrupts the 
expression of core pluripotency-associated genes and attenuates mESC self-renewal 
without inducing differentiation. These regulatory effects are mediated by rapid and 
direct destabilization of Brf1 targets, such as Nanog mRNA. Interestingly, enhancing Brf1 
expression does not compromise mESC pluripotency, but does preferentially regulate 
differentiation to mesendoderm by accelerating the expression of primitive streak 
markers. Together, these studies demonstrate that FGF signals utilize targeted mRNA 
degradation by Brf1 to enable rapid post-transcriptional control of gene expression. 
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Chapter 1  
Introduction 
 Embryonic stem cells (ESCs) hold great promise for the development of novel 
therapeutic strategies (1). Owing to their capacity for multi-lineage differentiation, 
diseased or damaged tissues can be replaced outright, rather than relying on palliative 
care and the body’s tolerance for wound healing (2). The discovery of ESCs thus heralds 
the age of regenerative medicine. ESCs can be used to rejuvenate non-regenerative 
tissues, such as the central nervous system, to correct deformities in tissue architecture 
and function (3). They can also serve as models for disease, and be modified for the 
treatment of genetic deficiencies or disorders (4, 5), to significantly improve a patient’s 
quality of life. The development of ESC based strategies should provide safe and 
effective treatments for numerous pathologies.  
However, while many potential medical applications for ESCs have been 
proposed, few have been implemented (6). In the decades following their discovery, the 
pace of clinical translation has lagged far behind the still basic science into what makes 
ESCs tick. In cell culture, ESCs are prone to differentiation, and research remains heavily 
focused on understanding the molecular basis of their pluripotency and self-renewal (7-
9). To fully achieve the dream of regenerative medicine, we must first identify and 
control the regulatory factors which influence the biology and behavior of ESCs.  
Here we focus on intercellular signaling and its regulation of pluripotency and 
self-renewal. Changes in signaling pathway activity strongly regulate the stability of ESC 
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cultures, but the mechanisms through which these regulatory effects are mediated have 
not been identified. Our goal was to characterize these mechanisms, and ascertain their 
functional and developmental relevance.  
What are Embryonic Stem Cells? 
 ESCs are derived from the mammalian blastocyst, a pre-implantation embryonic 
structure composed of only 3 differentiated lineages: trophectoderm, primitive 
endoderm and epiblast (10, 11). The mammalian blastocyst is first hatched from the 
zona pellucida and attached to a bed of mouse embryonic fibroblasts in vitro. Under 
these conditions, epiblast cells grow out from the site of attachment and expand in 
great numbers, whereas extra-embryonic cells (trophectoderm and primitive endoderm) 
fail to proliferate. Stably propagating cultures of these self-renewing epiblast cells are 
called ‘embryonic stem cells’ because of their ability to differentiate into all somatic cell 
types including the germ cell lineage in vitro (10, 11). They can also be genetically 
modified using transgenic methods, and reintroduced into donor blastocysts to 
generate transgenic embryos, thus providing researchers with the technology to modify 
and propagate changes to the mammalian genome (12-14).  
 To circumvent the destruction of embryos, an alternative strategy was also 
developed to derive pluripotent cells. Terminally differentiated cells could be 
epigenetically reprogrammed to an ESC-like state by forced expression of pluripotency-
associated transcription factors (Oct4, Sox2, Kl4 and Myc in mouse cells; Oct4, Sox2, 
Lin28 and Myc in human cells) (15). These reprogrammed cells exhibited many of the 
characteristics of genuine embryonic stem cells (16). However, because of their distinct 
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method of derivation, they were called ‘induced pluripotent stem cells’ (iPSCs). The 
derivation of patient specific iPSCs, which bypassed issues of immunological tolerance, 
further encouraged the development of personalized medical treatments. However, like 
ESCs, iPSCs are unstable cell types that frequently undergo spontaneous differentiation 
in suboptimal cell culture conditions.  
The Role of Intercellular Signaling in Pluripotent Cells 
 ESC and iPSC cultures are stabilized by defined cell culture media formulations 
(17). The key constituents of these media formulations are factors that modulate 
signaling pathway activity. Activation or inhibition of specific signaling pathways can 
promote pluripotency and continued self-renewal, and reduce the incidence of 
spontaneous differentiation in cell culture. We describe each of these signaling 
pathways in greater detail, from a historical perspective, and discuss their possible 
mechanistic connection to pluripotency and self-renewal genes.  
Leukemia Inhibitory Factor Signaling 
The derivation of the first ESC lines required embryonic fibroblast feeder layers 
(10, 11). It was hypothesized that these feeder layers produced an unknown transacting 
signaling factor which stabilized ESCs in culture. Leukemia Inhibitory Factor (LIF) was 
identified in a screen for signaling ligands which could support the undifferentiated 
growth of mouse ESCs (18, 19). Supplementing ESC cultures with LIF eliminated the 
need for embryonic feeders.  
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LIF is part of the cytokine family of ligand/receptor systems, known to mediate 
developmental and homeostatic responses in the embryonic and adult mouse. As a 
cytokine, its regulation is often associated with the hematopoietic lineage, but it is 
known to be broadly expressed by other cell and tissue types. For example, LIF is 
secreted from the endometrium to promote an exit from embryonic diapause after 
periods of nutrient stress (20), and is essential for blastocyst implantation (21). LIF is 
also important for maintaining resident stem cell populations in the adult brain (22), 
inhibiting angiogenesis (23), promoting muscle regeneration (24), and suppressing 
inflammation associated pathologies (25). 
 LIF interacts with the heterodimeric cell surface receptor gp130/LIFR to activate 
the intracellular non-receptor tyrosine Janus kinase (JAK) (26) (Figure 1.1). Activated JAK 
then phosphorylates Stat protein second messengers, which shuttle to the nucleus to 
act as transcription factors. JAK kinase can also activate other second messenger 
pathways (27). For example, gp130/LIFR mediates a direct interaction with PI3 kinase, 
which regulates gene expression by activating Protein kinase B (PKB). Cytokine receptors 
can also associate with Ras via the adaptor protein SHC, which activates Erk MAP kinase 
signaling responses.  
 The activation of multiple second messenger pathways can have different effects 
on the maintenance of pluripotency and self-renewal. For example, upregulating Stat 
activity maintains pluripotency in the absence of LIF, indicating that the signaling 
pathway imparts its protective effects, in part, through Stat-mediated transactivation of 
pluripotency-associated genes (28). A constitutively active form of PKB can also support 
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mESC culture in the absence of LIF, as well (29). However, enhancing Erk MAP kinase 
signaling has been shown to rapidly induce mESC differentiation (30). These 
observations indicate that LIF is capable of activating numerous intracellular responses, 
which could have antagonistic functional and regulatory effects. However, with regards 
to LIF, it would appear that its ability to support pluripotency and self-renewal outweigh 
its destabilizing and differentiating effects.  
Bone Morphogenic Protein Signaling 
 Even in the presence of LIF, mouse ESCs require serum, indicating additional 
extrinsic signaling requirements. It was known that culturing mouse ESCs without serum 
strongly promoted neural differentiation. Thus, this serum derived factor was expected 
to be anti-neurogenic. These observations led researchers to Bone Morphogenic Protein 
(BMP), which inhibits neural differentiation via Smad transcription factors, and is known 
to be present in serum.  
 BMPs are a subdivision of the Transforming Growth Factor- (TGF-) superfamily 
of ligands and receptors, first identified as potent inducers of bone formation, but are 
now known to mediate diverse developmental processes in the embryonic and adult 
mouse (31). BMP ligands are homodimers, but can exist as heterodimeric pairs. These 
signaling ligands nucleate cell surface receptors to form a heterotetrameric receptor 
complex composed of two Type I (BMPRIA/B, ALK1 or ALK2) and two Type II (BMPRII, 
ACVR-I or ACVR-II) receptors (Figure 1.2). BMP ligands can exhibit a preference for 
specific Type I and Type II receptor combinations, which influences the signaling activity 
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perceived by recipient cells. The formation of a heterotetrameric BMP receptor complex 
activates intracellular serine/threonine kinase domains to permit phosphorylation and 
activation of Smad (1/5/8) second messengers, which function as transcription factors 
(Figure 1.2).  
The BMP pathway is thought to prevent mouse ESC differentiation by inducing 
the expression of Inhibitors of Differentiation (Id) proteins, which bind to and inhibit the 
activity of pro-neural basic Helix-loop-Helix transcription factors that are expressed in 
ESCs (32). However, it has also been shown to regulate the overall receptivity of mouse 
ESCs to differentiation, by controlling the expression of pluripotency associated factors, 
such as Cdh1 (33).  
When ESCs were supplemented with LIF and BMP, self-renewal and pluripotency 
are maintained even in basal media (N2B27) (32). Thus, the discovery of LIF and BMP 
identified the minimal set of signaling pathway activities that were required to stabilize 
mouse ESCs in culture.  
Discrepancies between embryonic and cell culture signaling requirements 
Knockout phenotypes in the early mouse embryo suggested a possible role for 
Fibroblast Growth Factor (FGF) and Erk MAP kinase signaling as well (34). Loss of either 
FGF or Erk MAP kinase signaling compromised normal pre-implantation development by 
promoting epiblast at the expense of primitive endoderm (35, 36), while enhancing FGF 
or Erk MAP kinase signaling had the opposite effect (37). By contrast, LIF and BMP 
deficiencies had no effect on the development of pre-implantation mouse embryos. 
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How does the in vivo requirement for FGF and Erk MAP kinase relate to the in vitro 
dependence of mouse ESCs on LIF and BMP?  
Researchers discovered that inhibition of FGF and its second messenger pathway 
Erk MAP kinase functionally replaced the requirement for LIF and BMP (38). LIF/Stat and 
BMP/Smad coincidentally regulated similar sets of downstream targets as FGF/Erk, and 
antagonized the differentiating effects of FGF/Erk MAP kinase signaling through indirect 
mechanisms (39). Maintaining the activity of exogenous signaling pathways (i.e. LIF and 
BMP) was therefore not required, as long as the activity of destabilizing signaling 
pathways (i.e. FGF/Erk) remained suppressed.  
In agreement with these observations, using FGF/Erk MAP kinase signaling 
inhibitors enhanced the efficiency of ESC derivation from recalcitrant mouse strains (40, 
41). FGF/Erk MAP kinase signaling inhibitors also permitted the first ever derivation of 
Rat ESCs, which cannot be supported by LIF and BMP alone (42). It was thus proposed 
that FGF/Erk MAP kinase was the key signaling pathway through which rodent ESCs are 
controlled (43).  
Fibroblast Growth Factor Signaling 
FGFs are secreted growth factors, which bind to FGF-specific receptor tyrosine 
kinases (FGFRs) (Figure 1.3). This interaction occurs in association with heparin sulfate 
proteoglycans (HSPGs), which coat the surface of cells and are often regarded as 
necessary cofactors for signaling. Upon receptor activation, docking proteins aggregate 
on the intracellular side of the receptor in a phosphorylation-dependent manner, to 
pass the activation signal to second messenger pathways.  
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The second messengers downstream of FGFR are intracellular kinase cascades 
(44) (Figure 1.3). For example, FGFRs frequently activate the Erk MAP kinase pathway 
via Ras, which is a Serine-Proline/Threonine-Proline directed kinase. Erk is known to 
regulate numerous cellular functions and activities such as cell division, DNA replication, 
gene expression and differentiation. FGFRs can also activate PI3 kinase directly. The 
activity of PI3 kinase promotes cell survival by inhibiting apoptosis, increasing the 
activity of nutrient sensing pathways and preventing differentiation via PKB.  
The activation of both Erk MAP kinase and PI3 kinase signaling pathways could 
yield antagonistic functional and regulatory effects. Erk MAP kinase signaling promotes 
differentiation, whereas PI3 kinase maintains pluripotency and self-renewal. 
Interestingly, researchers determined that even though FGFRs have the capacity to 
signal through PI3 kinase, it does not appear to be a major regulator of this second 
messenger system in mouse ESCs (38). This observation could explain why disrupting 
FGF signaling primarily affects Erk MAP kinase signaling activity.  
Erk MAP Kinase Signaling 
 The components of the Erk MAP kinase pathway are well conserved, consisting 
of three kinases linearly activated in a cascade, invariant across all eukaryotes (45). For 
mammalian cells, the Erk MAP kinase pathway receives inputs from Ras, a membrane 
localized GTPase, which associates with activated cell surface receptors, such as FGFR.  
 Erk is the terminal kinase in the phosphorylation cascade, and it is the major 
effector of the Erk MAP kinase signaling pathway (46). Erk binds and phosphorylates its 
protein targets to regulate their function, stability and/or cellular localization. Binding 
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and phosphorylation are discrete events, as docking and phosphorylation are mediated 
by separate protein domains. Although Erk post-translationally regulates its targets, it 
phosphorylates transcription factors and post-transcriptional regulatory proteins, such 
as components of the miRNA pathway and RNA binding proteins. Thus, Erk has the 
capacity to regulate genes at all levels of expression.  
 Interestingly, even though Erk binding and phosphorylation motifs have been 
extensively characterized in vitro (47), and the effects of signaling activation on mouse 
ESCs are well studied (38), the identification of real and functionally important targets 
which mediate these effects has been challenging. Erk can also activate other regulatory 
kinases such as S6K and RSK, which have different target specificities. As such, the 
mechanistic basis for how Erk MAP kinase signaling destabilizes pluripotency and self-
renewal remains unclear.  
Pluripotency and self-renewal are maintained by a transcription factor network 
Rapid progress has been made in identifying key regulatory signaling pathways, 
such as FGF/Erk MAP kinase signaling. But the exact mechanisms through which these 
signaling pathways regulate the activity of pluripotency, self-renewal or differentiation 
factors have not been identified (48).  
Pluripotency, self-renewal and differentiation are cellular properties which are 
regulated by a network of transcription factors. The core members of this 
transcriptional network include Oct4, Sox2, Nanog, Klf4, Nac1, Dax1 and Zfp281 which 
form a module that regulates developmental genes, and Myc and Rex1, which support 
proliferation and self-renewal (49). These transcription factors bind enhancer sequences 
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which drive the expression of hundreds of pluripotency and self-renewal associated 
genes and can, in certain instances, promote the repression of differentiation factors 
(50). 
Compromising the expression of any core transcription factor can destabilize the 
ESC transcription factor network. These regulatory effects may also be dose-dependent. 
For example, enhancing Oct4 expression by 50% induces differentiation to 
mesendoderm, but downregulation of Oct4 by 50% causes primitive endoderm 
differentiation (51). In addition, controlling the expression of individual transcription 
factors can compensate for a deficiency in others. For example, enhancing Oct4 
expression maintains pluripotency in cells devoid of Sox2 (52). Finally, sustained 
expression of specific factors can reinforce the expression of all others to maintain 
pluripotency, as is the case with Nanog (53).  
These observations indicate that signaling-dependent control of any core 
transcription factor can strongly impact the stability of mouse ESCs (Figure 1.4).  
The homeodomain protein Nanog is regulated by Erk MAP kinase signaling 
 FGF/Erk MAP kinase signaling strongly regulates the expression of Nanog (37). 
The homeodomain protein Nanog was first identified in a screen for transcription 
factors which, when overexpressed, could maintain pluripotency in the absence of LIF. 
Since then, it has been shown that Nanog maintains the most naïve state of 
pluripotency (54), and is absolutely required for germline differentiation (55). 
Knockdown or knockout of Nanog greatly destabilizes their culture and promotes rapid 
differentiation (55, 56). Although the regulation of Nanog has been extensively studied 
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at the promoter, mRNA and protein level, mechanisms that connect FGF/Erk MAP 
kinase signaling to its regulation have not been identified (48).  
To better understand how FGF/Erk MAP kinase signaling regulates pluripotency 
and self-renewal gene circuits, we explored this specific regulatory relationship further, 
to uncover novel mechanistic connections and molecular players, which could have a 
broader role in the regulation of other key developmental transcription factors. 
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Figures 
 
 
Figure 1.1 – The LIF/JAK Signaling Pathway. (1) LIF brings together gp130 and LIFR 
surface receptors to form a heterodimeric receptor complex that activates JAK kinase 
(green). (2) JAK kinase can phosphorylate Stat (red), (3) which can then forms dimers, (4) 
and shuttle to the nucleus as a transcription factor. JAK can also activate PI3 kinase and 
Erk MAP kinase second messenger pathways.   
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Figure 1.2 – The BMP Signaling Pathway. (1) BMP homodimers and heterodimers 
nucleate four surface receptors (two Type I and two Type II receptors). (2) Type I 
receptors within the heterotetrameric receptor complex can phosphorylate the C-
terminal domain of Smad1/5/8 proteins, (3) to permit their trimerization with co-Smads 
(purple). (4) Activated Smad trimers shuttle to the nucleus to modulate transcription.     
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Figure 1.3 – The FGF Signaling Pathway. (1) FGF in association with heparin sulfate 
proteoglycans permit homodimerization of FGFR. Homodimerization of cell surface 
receptors greatly enhances their intrinsic tyrosine kinase activity, (2) leading to the 
phosphorylation of several adaptor proteins (green) which dock the intracellular 
domain. (3) Adaptor proteins channel the activation signal to Erk MAP kinase and PI3 
kinase signaling pathways. (4) Terminal kinases within these pathways phosphorylate 
transcription factors, among other possible protein targets.    
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Figure 1.4 – Signaling pathways regulating mouse ESCs.  LIF/Stat, FGF, Erk MAP kinase, 
BMP/Smad and WNT/-Catenin signaling influence the pluripotency, self-renewal and 
differentiation in mouse ESCs. They can have stabilizing (green lines) or destabilizing 
(red lines) effects. Signaling pathways are stimulated by providing exogenous signaling 
ligand, such as for LIF and BMP. Alternatively, signaling pathway activity can also be 
modulated using pharmacological inhibitors, such as CHIR (targets GSK3), PD173074 
(targets FGF receptors) and PD184352 (targets MEK1/2). The mechanistic connection 
between these signaling pathways and the molecular regulators of pluripotency, self-
renewal and differentiation (italicized) remains unclear.  
  
16 
 
Chapter 2 
FGF/Erk MAP kinase signaling utilizes post-transcriptional regulatory mechanisms in 
mouse ESCs. 
(This chapter was adapted, in part, from (57)) 
Introduction 
Mouse ESCs are trapped in a unique developmental state which allows them to 
proliferate without differentiating. This developmental state is stabilized by 
transcription factors, of which an increasing number have been shown to play 
indispensable roles. A core network of less than 20 factors is thought to support the 
most critical functions by driving the expression of pluripotency-associated genes, and 
activating repressors of differentiation cues or markers.  
Intercellular signaling regulates this transcription factor network via second 
messenger proteins, which can have stabilizing or destabilizing effects. For example, 
FGF/Erk MAP kinase signaling is known to destabilize mESC pluripotency and self-
renewal, but it may do so through numerous transcriptional, post-transcriptional and 
post-translational mechanisms. FGF/Erk MAP kinase signaling is a well-characterized 
signaling pathway, but very little is known about how it is mechanistically connected to 
the regulation of pluripotency genes.  
How can candidate mechanisms be identified? Among the most well-
characterized pluripotency factors, Nanog expression is known to be strongly regulated 
by FGF/Erk MAP kinase signaling (10). The anti-correlation between FGF/Erk MAP kinase 
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signaling activity and Nanog expression is well-documented in vitro and in vivo (37). To 
connect FGF/Erk MAP kinase signaling to pluripotency and differentiation gene circuits, 
we explored the dynamics of this regulatory relationship further to uncover novel 
mechanistic connections and their molecular players. 
Materials and Methods 
Nanog Reporter Cell Line 
We used mESCs carrying a histone2B-yfp reporter driven by the endogenous 
nanog promoter [v6.5 mESCs, Strain: (C57BL/6 x 129S4/SvJae), F1] to explore the 
connection between Nanog expression and FGF or Erk MAP kinase signaling (Figure 2.1). 
Stable integration of the histone2B-yfp reporter into the nanog locus inactivated one of 
the nanog alleles, which reduced overall Nanog expression levels in these cells. 
However, these reporter cell lines are haplo-sufficient and remain pluripotent (58).  
Immunohistochemistry and Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) Timecourses 
To readout changes in protein level in response to FGFR or MEK1/2 inhibition, 
with 200nM PD173074 or 5uM CI-1040, respectively, we immunostained inhibitor 
treated reporter cell lines with a polyclonal Nanog antibody (Bethyl Labs, A300-397A, 
1:1000). Cultures were harvested with 0.25% Trypsin-EDTA, dispersed into single cell 
suspensions and added to an equal volume of 4% Formaldehyde. Cells were pelleted, 
resuspended in 10% FBS in PBS to block, gently pelleted again, and then stained with 
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primary and secondary antibodies at 4C, overnight. Before flow cytometry analysis, 
cells were pelleted and resuspended in 2.5 mg/ml BSA in 1xHBSS. All samples, stained 
and unstained, were analyzed with a Miltenyi Biotech VYB flow cytometer. 
Compensation and background correction were applied post-acquisition.  
In parallel, we tracked mRNA level changes. Total RNA was harvested with QIAzol 
reagent (Qiagen, 79306), after which cDNAs were amplified and analyzed using qRT-
PCR. A single qPCR reaction was composed of 0.5ul of cDNA, primers or primers with 
probes, and qPCR reaction mix (diluted to a final volume of 10ul). For qPCR experiments 
using TaqMan/hydrolysis probes (5’ Dye: FAM, 3’ Quencher: Zen/Iowa Black FQ) or 
primers, cDNAs were profiled with SsoFast Supermix Reagent (Bio-Rad) using the 
manufacturer recommended protocol. In brief, we employed a 2-step thermocycling 
protocol (an initial 30 second 95C melt, followed by 40 cycles of 5 second 95C melt 
and 10 second 60C anneal/extend). 
Two-dimension (2D) gel electrophoresis 
Two-dimension (2D) gel electrophoresis was used to detect phosphorylated 
residues. Cells were harvested and lysed in detergent-free lysis buffer (8M Urea, 200mM 
NaCl and 40mM HEPES pH 8.0) at a concentration of 2x106 cells per 100ul. Lysates were 
supplemented with Complete Protease Inhibitor (Roche) and Phosphatase Inhibitor 
Cocktail I and II (Sigma) when appropriate. Samples were separated on a pH gradient 
(pH 3.5 to pH 10) followed by molecular weight separation via SDS-PAGE. Samples 
treated with calf intestinal phosphatase (CIP) were first dialyzed a thousand-fold using 
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Amicon Ultra Centrifugal Filter Units (3kDa) to remove Urea and inhibitors. Samples 
were then incubated with 10 Units of CIP for 3hrs at 37°C in NEB Buffer “3” before 
separation by 2D-gel electrophoresis. 
In vitro Phosphorylation Assay 
Direct phosphorylation by Erk MAP kinase was screened in vitro. A total of 5ug of 
NiNTA purified, recombinant produced Nanog/Myc-6His, was incubated with 200ng 
Human Erk1 (Cell Signaling Technologies) in Kinase Buffer (25mM Tris-HCl, 5mM -
glycerophosphate, 2mM DTT, 0.1mM Na3VO4, 10mM MgCl2) supplemented with 100uM 
ATP, [-32P]. Radioactive labeling was screened using a phosphorimager.  
Nanog mRNA half-life Measurement  
To measure changes in Nanog mRNA half-life, mESC cultures were co-transfected 
with a reverse Tet (rTet) expression plasmid (PGK-H2B-mCherry/T2A/rTet) and either 
CMV(2xTetO)-H2B-YFP or CMV(2xTetO)-Nanog (with or without AREs) at 19:1 ratio by 
mass. Culture media was then transitioned to media containing FGF4 and Heparin 
(10ng/ml and 10ug/ml respectively) or PBS to determine the regulatory effect of ERK 
MAP kinase signaling in fgf4-/- cells. To stop transcription from the CMV-TO promoter, 
Doxycycline was added to obtain a final concentration of 1ug/ml which permits binding 
of rTet to Tet operator sequences. Changes in the abundance of H2B-YFP or Nanog 
mRNA relative to Gapdh, Sdha and Tbp housekeeping genes was measured using qRT-
PCR. To distinguish from endogenous Nanog mRNA, we developed a primer set that 
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specifically recognized the 5’UTR of Nanog expressed only from the CMV(2xTetO) 
promoter. 
Results and Discussion 
We used pharmacological inhibitors of signaling to disrupt the regulation of 
Nanog expression (Figure 2.2.A). We discovered that in response to FGFR inhibition, 
Nanog protein levels increased in two distinct stages: An initial response was observed 
within 5 hours, with a second, more gradual increase occurring over the next 20 hours 
(Figure 2.2.B, blue solid line). Interestingly, the initial rapid increase in Nanog protein (≤ 
5hrs) could not be explained by a corresponding increase in transcription, as YFP 
fluorescence increased only after a short delay (Figure 2.2.B, blue dotted line).  We also 
observed the same two-stage response to MEK1/2 inhibition (Figure 2.2.B, red solid and 
dotted lines). These results indicate that in addition to transcriptionally regulating 
Nanog expression, FGF and Erk MAP kinase signaling independently regulate Nanog 
protein levels on a much faster timescale.  
Previous work has shown that a cis-regulatory element in the proximal nanog 
promoter is required for downregulating Nanog transcription by FGF/Erk MAP kinase 
signaling (59) (Figure 2.3). This region of the nanog promoter contains a transcriptional 
enhancer, composed of DNA sequences surrounding a conserved Oct4/Sox2 binding 
motif (60). Ablating this Oct4/Sox2 enhancer compromises the transcriptional regulation 
of Nanog by FGF/Erk MAP kinase signaling (59). Since Oct4 and Sox2 are known to 
nucleate many pluripotency associated transcription factors, FGF/Erk MAP kinase 
signaling thus mediates its repression by first downregulating one or more of these 
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activating transcription factors (Figure 2.3) (49). Nanog has been shown to auto-regulate 
its own transcription. Post-translational regulation of Nanog could compromise 
enhancer function to permit signaling dependent control over the nanog promoter, and 
could explain why the transcriptional response to FGFR and MEK1/2 inhibitors is delayed 
relative to protein level changes.  
Erk may influence Nanog protein stability directly via phosphorylation (Figure 
2.4.A). We determined that Nanog protein is phosphorylated (Figure 2.4.B), and multiply 
phosphorylated Nanog accumulates when the proteasome is inhibited (Figure 2.4.C). 
However, Nanog is not phosphorylated by Erk MAP kinase (Figure 2.5). These data do 
not discount the possible role of other unidentified kinases, which operate downstream 
of Erk1/2 activation, and for which consensus binding motifs have not been identified.  
In the absence of a direct post-translational mechanism that could account for 
protein level changes, another possible explanation is that regulation of Nanog mRNA 
leads to corresponding changes in Nanog protein. Erk MAP kinase signaling might 
regulate the biogenesis of microRNAs (61), which would then regulate Nanog mRNA 
translation and stability directly. Recent studies implicate several miRNAs in the 
maintenance of self-renewal and differentiation (62, 63), and a few have been shown to 
target Nanog mRNA (64).  
To explore this possibility, we profiled changes in mature miRNA expression in 
fgf4-/- cells after brief stimulation with HrFgf4/Heparin using microarrays. Differentiation 
associated miRNAs were upregulated after 5 hours of FGF signaling activation (Figure 
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2.6). Notably, miR-296-3p expression was upregulated 2-fold by FGF, which has been 
shown in previous studies to directly regulate Nanog expression (64).  
FGF signaling reduces Nanog mRNA levels (Figure 2.7). We discovered that 
transfecting fgf4-/- mESCs with an antago-miR against miR-296-3p could not block the 
downregulation of Nanog mRNA by FGF4/Heparin (Figure 2.7). Furthermore, transient 
knockdown of Dicer and/or Drosha expression using siRNAs could not alter Nanog or 
YFP mRNA levels after 36 hours (Figure 2.8). These data indicate that microRNAs may 
not play a central role in the regulation of Nanog expression.  
Interestingly, the response of Nanog mRNA to FGF or Erk MAP kinase signaling 
inhibitors was similarly rapid. Using qRT-PCR, we compared Nanog transcript levels to 
Histone2B-yfp mRNA levels. Here, we also observed a two-stage response to the 
inhibition of FGFR or MEK1/2, with changes in mRNA occurring well before changes in 
transcription, and on a similar timescale as protein level changes (compare Figure 2.2.B 
and 2.9.B). We note strong similarities between Nanog mRNA and protein level changes 
(compare Figure 2.2.B and 2.9.B). It is possible that changes in protein levels simply 
reflect changes in mRNA abundance. 
We hypothesized that FGF/Erk MAP kinase signaling rapidly activated or 
enhanced the expression of an RNA binding protein, which then post-transcriptionally 
regulated Nanog mRNA. We inspected the Nanog mRNA sequence for protein binding 
motifs and discovered several AU-rich elements (AREs) in the 3’UTR (Figure 2.10.A). AU-
rich element RNA binding proteins (AUBPs) have been shown to regulate mRNA stability 
and translational efficiency in other cellular contexts (65). To determine whether 
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Nanog’s AREs are post-transcriptionally regulated by AUBPs in response to FGF/Erk MAP 
kinase signaling (Figure 2.10.B), we measured changes in the Nanog mRNA half-life in 
the presence or absence of AREs, and in the presence or absence of FGF signaling. Using 
fgf4-/- mESCs, we determined that the half-life of Nanog mRNA is 2.5 ± 0.4 hours (± 
s.e.m.) without FGF4/Heparin and 1.5 ± 0.3 hours (± s.e.m.) with Fgf4/Heparin (Figure 
2.10.C, left). Removing all 3’UTR ARE sites [ARE (1,2,3)] eliminated the post-
transcriptional regulation of Nanog mRNA by FGF signaling (Figure 2.10.C, middle). A 
negative control mRNA (H2B-YFP) which does not have AREs is also insensitive to 
changes in FGF signaling (Figure 2.10.C, right).  
Together, these data show that Nanog’s AREs are post-transcriptionally 
regulated by FGF signaling, highlighting the potential regulatory significance of AUBPs as 
signaling intermediates and as regulators of development. 
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 Figures  
 
 
 
 
 
 
 
 
Figure 2.1 – Fluorescent reporter of Nanog transcription. A diagram of a histone2b-
IRES-puromycin-SV40pA knock-in cassette used to replace exon1 of the nanog gene. 
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Figure 2.2 – FGF/Erk MAP kinase signaling regulates Nanog protein expression faster 
than Nanog transcription. (A) Cartoon of the FGF/Erk MAP kinase signaling pathway 
and its connection to Nanog. This regulatory connection was explored using FGFR and 
MEK1/2 inhibitors, PD173074 (100ng/ml) and CI-1040 (5uM), respectively. (B) The effect 
of FGF or MEK inhibition on Nanog protein levels and transcription over a 20 hour time course [ 
SEM, n=4].  Values show fold change in concentration relative to an untreated negative control 
(DMSO only).  
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Figure 2.3 – FGF regulates the Nanog proximal promoter. FGF regulates factors which 
bind the Oct/Sox enhancer, approximately -180 from the transcription start site, to 
downregulate Nanog transcription. 
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Figure 2.4 – Nanog protein is phosphorylated. (A) Erk could phosphorylate Nanog 
protein directly. (B) 1-dimension SDS-PAGE blotting for endogenous Nanog in the 
presence and absence of proteasome inhibitor (MG-132). Note the slight change in 
electrophoretic mobility after proteasome inhibition. (C) Each panel shows 2-dimension 
western blot for Nanog under the indicated conditions: Panels B and D include 
proteasome inhibitor.  Panels C and D include Calf Intestinal Phosphatase treatment. 
Red arrows show that Nanog accumulates acidic post-translational modifications when 
mESC cultures are grown with proteasome inhibitor. Blue arrows indicate the 
accumulation of less acidic forms of Nanog protein after protein lysates are treated with 
phosphatase, which confirms the existence of phospho-modifications. 
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Figure 2.5 – Nanog protein is not phosphorylated by Erk. Nanog protein contains kinase 
docking sites (Erk and Cyclin) and phosphorylation motifs overlapping a PEST domain, 
which could link phosphorylation events to protein destabilization. However, 
recombinant Nanog-Myc/6His was not phosphorylated by Erk1 or Cdk1/CycB in vitro. By 
contrast, the Erk1 and Cdk1/CycB targets, GST-Elk1 and GST-Rb1, respectively, could be 
labeled with -32P-ATP.  
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Figure 2.6 – FGF upregulates miR-296-3p expression. Mature miRNA expression was 
profiled in the presence (black bars) or absence (white bars) of FGF4/Heparin (5 hours) 
in fgf4-/- R1 mESCs. Plotted is the expression of known differentiation associated 
miRNAs, relative to miR-290-5p (positive control). Note the 2-fold change in miR-296-
3p, a miRNA that has been shown to post-transcriptionally regulate Nanog mRNA (64).  
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Figure 2.7 – Anti-miR-296-3p cannot block FGF-dependent regulation of Nanog. (A) 
miR-296-3p may act as a regulatory intermediate of FGF/Erk MAP kinase signaling. (B) 
Transfecting fgf4-/- R1 mESCs with anti-miR-296-3p [10nM] cannot prevent the 
downregulation of Nanog mRNA by FGF4/Heparin (5 hours). 
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Figure 2.8 – miRNAs do not regulate Nanog mRNA and transcription levels. (A) 
Western blots showing successful knockdown of Dicer and Drosha after 24 hours. (B) 
Rbl2 is upregulated in response to Dicer and Drosha knockdown after 36 hours (positive 
control). (C) Dicer or Drosha knockdown does not affect Nanog mRNA or transcription 
levels in the Nanog reporter cell line [ SEM, n=4]. 
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Figure 2.10 – FGF/Erk MAP kinase signaling regulates Nanog mRNA expression faster 
than Nanog transcription. (A) Cartoon of the FGF/Erk MAP kinase signaling pathway 
and its connection to Nanog. This regulatory connection was explored using FGFR and 
MEK1/2 inhibitors, PD173074 (100ng/ml) and CI-1040 (5uM), respectively. (B) The effect 
of FGFR and MEK1/2 inhibition on Nanog mRNA levels and transcription over a 10-hour 
time-course [ SEM, n=4]. Note the rapid change in protein and mRNA level and slower 
transcriptional response [ SEM, n=3].  
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Figure 2.10 – Nanog is regulated by AU-rich element RNA binding proteins.  (A) 
Illustration indicating the relative location and sequence of AU-rich elements in the 
3’UTR of Nanog. (B) AUBPs may act as regulatory intermediates of FGF/Erk MAP kinase 
signaling. (C) Changes in mRNA half-life were profiled in the presence (blue data points) 
or absence (black data points) of FGF signaling in fgf4-/- mESCs for wild-type Nanog 
mRNA (top), mutant Nanog mRNA with deleted AREs (ARE (1,2,3)) (middle), and H2B-
YFP mRNA (bottom) [ SEM, n = 4].  Red dashed lines indicate half the initial mRNA 
concentration. 
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Chapter 3  
FGF/Erk MAP kinase signaling regulates the expression of Brf1, an AU-rich element 
RNA binding protein. 
(This chapter was adapted, in part, from (57)) 
Introduction 
AU-rich element mRNA binding proteins (AUBPs) represent an important class of 
regulators required for the proper development of embryonic and adult tissues in the 
mouse (66), but whether they have developmentally important roles in mouse 
embryonic stem cells (mESCs) remains unclear. A recent proteomic survey identified 
more than 500 mRNA binding proteins, several of which are AUBPs (67). Independent of 
the microRNA pathway, AUBPs are known regulators of splicing, mRNA stability, 
translational efficiency and RNA transport (68), and could provide an additional layer of 
developmental regulation that complements other pluripotency and self-renewal 
mechanisms. AUBPs are essential in many developmental systems, such as during 
hematopoiesis, neurogenesis, germ cell commitment and placental morphogenesis (69-
71). Their absence or misregulation can be lethal, and often promotes disease 
progression (72-74). Despite growing interest in the many functions of AUBPs, their 
regulation and function in mESCs remains poorly understood.  
The expression and activity of AUBPs is known to be regulated by growth factor 
signaling in many cellular contexts (75, 76). In mESCs, the FGF/Erk MAP kinase signaling 
pathway is a central regulator of self-renewal, pluripotency and differentiation (43, 48). 
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Although much is known about the developmental effects of FGF/Erk MAP kinase 
signaling inhibition or activation (30, 38), the regulatory mechanisms employed 
downstream of Erk1/2 often remain unclear. Various transcriptional, post-
transcriptional and post-translational mechanisms are engaged to regulate target genes 
(44). As part of this signaling cascade, AUBPs could mediate rapid signaling-dependent 
responses, but this potential role has not been investigated. 
Materials and Methods 
We measured changes in AUBP mRNA level using qRT-PCR. As described 
previously, total RNA was harvested with QIAzol reagent (Qiagen), after which cDNAs 
were amplified and analyzed using qRT-PCR. Further information regarding qRT-PCR 
reaction conditions and reagents can be found in the Supplementary Methods section.  
For Western blot analysis, cells were harvested and lysed with SDS Loading 
Buffer (1% SDS, 10% glycerol, 0.01% bromphenol blue and 60mM Tris pH 6.8) at a 
concentration of 1x106 cells per 100ul. To profile nuclear and cytoplasmic protein 
fractions, harvested cell pellets were first processed with NE-PER Nuclear Protein 
Extraction Kit, before the addition of SDS Loading Buffer. 
Results and Discussion 
AUBP expression in mESCs has been documented by several groups (67, 74, 77). 
The known sensitivity of AUBPs to growth factors suggested that these proteins could 
be regulated by FGF/Erk MAP kinase signaling (76, 78). To explore this potential 
regulatory connection, we first profiled the transcriptome of E14 mESCs using high-
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throughput sequencing to determine which AUBPs are actively expressed (Figure 3.1.A). 
We identified several classes of AUBPs, including: (1) members of the Zfp36 protein 
family [TTP (zfp36), Brf1 (zfp36l1) and Brf2 (zfp36l2)], which are known to play critical 
roles during hematopoiesis by destabilizing Cytokine and Notch-Delta signaling-
associated mRNAs, (2) members of the Hu protein family [HuR (elavl1), HuB (elavl2)], 
which stabilize their mRNA targets and are known to actively regulate germ cell 
development, and (3) Auf1 (hnrnpd), which can stabilize or destabilize mRNA and 
modulate inflammation in the adult mouse (65).  
To determine whether any of the detected AUBPs was regulated by FGF/Erk 
MAP kinase signaling, we measured changes in their expression in response to 
pharmacological inhibitors of MEK1/2. We discovered that TTP and Brf1 responded 
strongly to MEK1/2 inhibition, with mRNA levels downregulated greater than 2-fold 
after 5 and 10 hours (Figure 3.1.B). Brf2, Auf1 and KHSRP mRNA levels were also slightly 
downregulated. Interestingly, three out of five of these responding genes are members 
of the Zfp36 protein family (Figure 3.1.B, red bracket). 
We explored the regulatory connection between Zfp36 AUBPs and FGF/Erk MAP 
kinase signaling further by measuring how TTP, Brf1 and Brf2 responded to short and 
long periods of MEK1/2 inhibition (Figure 3.2.A). Incubation with MEK1/2 inhibitor 
resulted in a rapid reduction in TTP, Brf1 and Brf2 mRNA level as gauged by RT-qPCR 
(Figure 3.2.B). Brf1, Brf2, and to a lesser extent, TTP mRNA level changes were 
significant within 1 hour of inhibitor treatment (Figure 3.3.A), and continued to decrease 
after 7.5 hours of inhibition (Figure 3.2.B). However, after 10 hours, TTP and Brf2 mRNA 
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expression recovered, while Brf1 expression remained suppressed (Figure 3.2.B). Since 
the pharmacological inhibitor provides continuous suppression of Erk MAP kinase 
signaling (Figure 3.3.B), these data indicate that TTP and Brf2 mRNA respond only 
transiently (t < 10 hours) to changes in Erk MAP kinase signaling, whereas Brf1 mRNA 
maintains a sustained response to the level of Erk MAP kinase signaling. 
Protein level changes were also rapid, with a 30% reduction in TTP and a 50% 
reduction in Brf1 within 1.5 hours of inhibitor treatment (Figure 3.2.C and 3.3.C). 
However, whereas Brf1 protein levels continued to fall for the remainder of the time 
course, reaching 10-fold less protein by 30 hours, TTP protein levels recovered and 
increased above DMSO treated controls (Figure 3.2.C). These data indicate that the 
regulation of TTP protein becomes distinct from the regulation of TTP mRNA at later 
times (compare Figure 3.2.B and 3.2.C). We note that in other cellular contexts, direct 
phosphorylation of TTP protein by Erk1/2 has been shown to reduce its stability (75). 
Furthermore, Zfp36 AUBPs also contain AU-rich sequences in their own mRNAs, which 
enable direct auto- and cross-regulation (Figure 3.3.D). These mechanisms could explain 
why TTP protein and mRNA levels respond differently after prolonged MEK1/2 
inhibition. In contrast, Brf2 protein levels were much less affected, dropping slightly at 
10 hours, and then recovering at later time points. Thus, at both the mRNA and protein 
levels, Brf2 responds more weakly to these perturbations (Figure 3.2.C). These results 
indicate that AUBP levels respond to changes in Erk MAP kinase signaling with different 
kinetics. 
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To further validate these findings, we checked whether upregulating FGF 
signaling could produce opposite results to inhibition. We added FGF4/Heparin to fgf4-
/- R1 mESCs (strain FD6), in order to activate Erk MAP kinase signaling (Figure 3.2.D) 
(79). TTP, Brf1 and Brf2 mRNA levels increased within 5 hours of ligand addition, with 
similar changes at the protein level (Figure 3.2.E and 3.2.F). These changes occurred 
specifically within the cytoplasmic compartment, consistent with a role for these AUBPs 
in regulating targeted degradation of mature mRNAs (Figure 3.2.F). Together, these 
results indicate Zfp36 protein expression responds rapidly to both increases and 
decreases in FGF/Erk MAP kinase signaling activity, leading to both transient (TTP, Brf2) 
and sustained (Brf1) regulatory responses.  
Among the Zfp36 AUBPs, FGF/Erk MAP kinase signaling most strongly regulated 
the expression of Brf1 in pluripotent conditions (Figure 3.2). During differentiation, Brf1 
expression is similarly dynamic, and continued to be regulated by FGF/Erk MAP kinase 
signaling (Figure 3.4.A). The 2-fold reduction in Brf1 expression over 4 days of LIF 
withdrawal (Figure 3.4.A) tracked concomitant changes in FGF4 expression (Figure 
3.4.B), and the downregulation of the Erk MAP kinase target genes Spred2 and Spry2 
(Figure 3.4.B). Could Brf1 mechanistically link FGF/Erk MAP kinase signaling to the post-
transcriptional regulation of Nanog mRNA? 
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Figures 
 
 
 
 
 
Figure 3.1 – Erk MAP kinase signaling regulates AUBP expression in mESCs. (A) 
Distribution of average transcript abundances (FPKM) from two total RNA biological 
replicates. Highlighted are notable mESC pluripotency and differentiation genes (gray 
triangles), which were used to distinguish actively expressed genes (mean FPKM ≥ 5, 
7,194 genes) from the gene expression background (mean FPKM < 5, 11,119 genes). 
FPKM = 5 denoted by red dashed line. Well-characterized and actively expressed AUPBs 
are highlighted (orange triangles). (B) Profiling changes in AUBP expression using RT-
qPCR in response to a pharmacological inhibitor of MEK1/2 (CI-1040/PD184352) after 5 
and 10 hours. 
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Figure 3.2 - FGF/Erk regulates the expression of Zfp36 RNA-binding proteins.  (A) 
Cartoon depicting the potential relationship between FGF/Erk MAP kinase signaling and 
AUBP expression. Whereas the addition of Fgf4/Heparin activates the FGF/Erk MAP 
kinase pathway, culturing cells with 5 uM PD184352/CI-1040 inhibits Erk1/2 activation. 
(B) A 30 hour RT-qPCR time course of TTP, Brf1, and Brf2 mRNA level changes in 
response to MEK1/2 pharmacological inhibitors [ SEM; n=3 for all time points], and (C) 
corresponding Western blots. (D) Western blot staining for Erk1/2 and phospho-Erk1/2 
(Thr202/Tyr204) showing pathway activation in cells stimulated with 10ng/ml FGF4 + 
10ug/ml Heparin for 15 minutes. (E) Changes in TTP, Brf1 and Brf2 after 5 hour 
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incubation with or without FGF4/Heparin as indicated [ SEM; n = 3]. (F) Western blot 
profiling of changes in TTP, Brf1 and Brf2 protein level in fgf4-/- mESCs after stimulation 
with FGF4/Heparin for 5 hours. To compare changes in intracellular localization, 
proteins were harvested sequentially as cytoplasmic [cyto] or nuclear [nuc] fractions, 
with -tubulin and TATA binding protein serving as localization controls.  
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Figure 3.3 – Rapid changes in Zfp36 expression at the mRNA and protein level. (A) A 
2.5 hour qRT-PCR time course of TTP, Brf1, and Brf2 mRNA level changes in response to 
MEK1/2 pharmacological inhibitors [ SEM; n=3 for t ≤ 2hrs; n=2 for t = 2.5hrs]. (B) 
Pharmacological inhibition of MEK1/2 with 5 uM PD184352/CI-1040 inhibits Erk1/2 
activation for >24 hours. (C) Representative Western blots of TTP, Brf1 and Brf2 protein 
levels for a 2.5 hour time course. (D) Zfp36 AUBPs contain AREs within their own 3’UTRs, 
and have the capacity to directly auto- and cross-regulate their own expression. siRNA 
knockdown of individual Zfp36 AUBPs (10nM final siRNA concentration) leads to 
corresponding protein level changes in the remaining Zfp36 AUBPs. Protein levels were 
assayed 36 hours after siRNA transfection by Western blot. 
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Figure 3.4 – Brf1 tracks changes in FGF/Erk during differentiation. (A) Changes in Brf1 
expression after LIF removal (blue line; light blue bounding boxes at each time point 
represent  SEM, n = 3), and its dependence on FGF or Erk MAP kinase signaling (white 
and black boxes, 3 hour inhibitor treatment) [ SEM, n = 3]. (B) Changes in FGF4, FGF5, 
FGFR1, Spred2 and Spry2 after LIF removal [ SD, n = 2].  
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Chapter 4  
Brf1 binds many pluripotency associated genes in vitro. 
(This chapter was adapted, in part, from (57)) 
Introduction 
Several AUBP families exist and have the capacity to bind numerous mRNA 
targets. AUBPs interact with mRNAs via a core (-UUAUUUAUU-) motif located in the 
3’UTR (80). This sequence is common, and can be found in the 3’UTR of 6% of mouse 
protein coding genes (Table 4.1). However, depending on the local sequence context 
surrounding the binding site, variation in this minimal motif could exist, to increase or 
decrease the association of AUBPs with target mRNAs. Previous work has already shown 
the existence of non-canonical AREs that mediate AUBP binding and regulation (81). The 
sequence determinants that permit regulation of target mRNAs have not been fully 
characterized.  
Transcriptome-wide identification of Brf1 targets has not been undertaken in any 
developmental or cellular system. To better understand the functional and 
developmental significance of Brf1 in mESCs, and to further characterize its mechanistic 
connection to Nanog, we performed a number of different immunoprecipitation studies 
which assayed for direct protein-to-RNA binding. 
Materials and Methods 
RNA immunoprecipitation sequencing (RIPseq) Procedure and Analysis 
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To identify Brf1 mRNA targets, we conducted RNA immunoprecipitation 
sequencing (RIPseq) (Figure 4.1.A). Briefly, cytoplasmic extract from approximately 
1x107 E14 mESCs was distributed equally among 2 samples and 2 controls. For sample 
reactions, 5ug of anti-Brf1/2 antibody was used for 50ul of magnetic protein A/G beads. 
For control reactions, 5ug of rabbit IgG with no immunoreactivity was used for 50ul of 
magnetic protein A/G beads. After stringency washes and proteinase K digestion, RNA 
was isolated using Qiazol reagent.  
RIP-purified RNAs and total RNA from E14 mESCs were prepared for sequencing 
using a TruSeq RNA Sample Prep kit. RNAs were fragmented to generate lengths of 
approximately 200 nucleotides, reverse transcribed with random hexameric primers to 
generate double stranded DNA, blunted, adenylated and ligated to Illumina sequencing 
adapters (150bp). DNA fragments were gel separated and all fragments running at 
350bp were extracted and amplified. Amplified DNA fragments were then sequenced 
using an Illumina HiSeq2000. 
Raw sequencing reads were trimmed (of 13nts from 5’ end) prior to Bowtie 
mapping using a mouse transcript annotation containing only protein coding genes 
(18,313 genes), derived from the NCBI37/mm9 genome build. Mapping statistics were 
generated using eXpress (82). For enrichment analysis, fragments per kilobase exon per 
million mapped reads (FPKM) were used as a measure of transcript abundance (83).  
We computed a statistic (       ) that represents the degree to which the 
abundance of the     transcript is enriched by antibody mediated RIP. This statistic uses 
differences in a transcript’s abundance after Brf1/2 antibody RIP (mean FPKMBRF,n ) 
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compared to rabbit IgG RIP (mean FPKMIgG,n), normalized by their initial abundance in 
total RNA before RIP (mean FPKMTotal,n ). This difference was further normalized by a 
penalty factor (   ), which accounts for a transcript’s tendency to be non-specifically 
purified, and is thus a saturating function of transcript abundance in the IgG control 
experiment:  
 
      
             
 
 
 
Where,  
      
             
               
 
 
      
             
               
 
 
        (    )        
 
Although       captures the level of non-specific association of a transcript with 
assay components (i.e., protein A/G beads, rabbit IgG, etc.), non-specific association of 
transcripts with immunoprecipitated RBP/RNA complexes could not be independently 
quantified, and could contribute a background to these       values. 
AUBP Pull-down Assay 
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To isolate AUBPs from cytoplasmic extracts in vitro, IL-2 and Nanog RNAs were 
produced in vitro using T7 Ampliscribe (Epicentre Technologies). These RNAs were then 
hybridized to biotin-DNA oligonucleotides at their 3’ end. 200 pmoles of IL-2 or Nanog 
RNA was used for 250 pmoles of biotin-DNA oligonucleotide. Hybridization reactions 
were added to 1mg streptavidin magnetic agarose beads (New England Biolabs). Crude 
cytoplasmic extracts used for protein pull down assays were obtained using NE-PER 
reagents (Thermo Scientific). RNA/DNA-bead conjugates were incubated in crude 
cytoplasmic extract for 1hr at 4°C, washed 5x with Binding Buffer [20mM Tris-HCl pH 
7.5, 50mM KCl, 1mM EDTA, 1mM DTT, 0.5% Triton-X 100 with RNAse inhibitors] and 
incubated in High Salt Elution Buffer [Binding Buffer + 1M NaCl] to collect RNA-bound 
protein fractions. Protein pull downs were analyzed via Western blot. 
 
Full description of high-throughput sequencing datasets can be found in (57). 
Results and Discussion 
We computed a statistic, denoted ERIP for each actively expressed transcript 
purified via RIPseq. ERIP represents the amount of mRNA co-precipitated with Brf1 
protein over non-specific background levels. Genes with high ERIP values were more 
likely to have AREs in their 3’UTR (Figure 4.1.B). For example, considering the transcripts 
most enriched by Brf1 immunoprecipitation (positive outliers, ERIP > 1.226, 418 genes), 
25.1% contained the minimal full consensus ARE and 60.0% contained the minimal 
partial consensus ARE. These percentages represent a 3 to 4-fold increase in ARE 
abundance relative to their frequency among all protein coding genes (Figure 4.1.B). 
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Moreover, several of the most highly enriched target genes were previously 
characterized as direct targets of Zfp36 proteins (e.g., Ier3, Mllt11 and Pim3), including 
Zfp36 proteins themselves (84, 85). Interestingly, based on our definition of the minimal 
ARE element, many highly enriched target genes do not contain consensus AREs. 
However, the existence of non-canonical (though still poorly characterized) AU-rich 
sequences has been documented, and could explain the enrichment of these mRNAs 
(81). Thus, the RIPseq assay can selectively enrich for mRNAs containing AU-rich 
elements. 
Several pluripotency-associated factors were detected in the Brf1-RIP fraction, 
potentially explaining the developmental effects of Brf1 overexpression. For example, 
the core pluripotency regulators Nanog (ERIP = 0.58) and Klf2 (ERIP = 7.15) were both 
enriched, and were within the top quartile of enriched targets. Nanog broadly inhibits 
mESC differentiation, and its expression is reduced as cells lose pluripotency and 
commit to extra-embryonic and somatic cell lineages in culture (53, 86). Klf2, along with 
Klf4 and Klf5, inhibits mesendoderm differentiation. Knockdown of Klf factors up-
regulates primitive streak markers, as well as Cdx2, a gene expressed in trophectoderm 
and extra-embryonic mesoderm (87). Also consistent with a role for Brf1 in promoting 
mesendoderm, the pluripotency factors Kdm4c (ERIP = 0.63) and Zfp143 (ERIP = 0.99) 
were enriched in the RIPseq assay. Knockdown of the lysine methyl-transferase Kdm4c 
is known to upregulate mesendoderm and extra-embryonic mesoderm markers (88). 
Zfp143 coordinates with Oct4 to transcriptionally activate Nanog. siRNA knockdown of 
Zfp143 rapidly initiates differentiation and promotes the expression of Fgf5, Cdx2 and 
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Cdh3, which are expressed in trophectoderm and cells that commit to extra-embryonic 
mesoderm (89). Understanding the regulation of these mRNAs may provide mechanistic 
insights into the Brf1-dependent control of gene expression, as well as its 
developmental effects in mESCs. 
To corroborate these RIPseq results, we assayed for direct binding of Brf1 to an 
enriched mRNA, in this case, Nanog (Figure 4.2.A). Previous work has shown that Nanog 
is strongly regulated by FGF/Erk MAP kinase signaling (36), and these effects are 
mediated, in part, by direct regulation of the Nanog promoter (59). Post-transcriptional 
regulation by Brf1 would provide an alternative mechanism to repress Nanog 
expression.  
We conducted an AUBP pull-down assay using RNA as bait (Figure 4.2.B, left). 
Wild-type RNA and variants with ARE sequence mutations were expressed in vitro and 
hybridized at their 3’ ends to DNA oligonucleotides coupled to magnetic microbeads. 
These RNA-microbead conjugates were then incubated with crude cytoplasmic protein 
extracts, and all proteins capable of binding hybridized RNAs were magnetically isolated 
and purified for further analysis.  
We used the 3’UTR sequence of IL-2 as a positive control, since it contains 
clusters of ARE sequences that are bound and regulated by Zfp36 AUBPs (90). Western 
blots showed that Brf1 could be purified from mESC lysates using a conjugated wild-type 
IL-2 sequence, but not using a mutant IL-2 lacking known AREs (Figure 4.2.B, right). Two 
Brf1 bands of different sizes were detected, possibly indicating the purification of 
different post-translationally modified forms of Brf1.  
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We next repeated the assay using Nanog mRNA as bait. The 3’UTR of Nanog 
mRNA is approximately 1kb, and contains three potential ARE elements: one full 
consensus (Site 1 in Figure 4.2.A) and two partial non-consensus sequences (Sites 2 and 
3 in Figure 4.2.A). Western blotting of these protein pull-downs indicated that Brf1 
bound to wild-type Nanog mRNA (Figure 4.2.B, right). Mutating the full-consensus ARE 
(Site 1) significantly reduced Brf1 binding. Removing the remaining two partial non-
consensus AREs (Sites 2 and 3) did not appear to further reduce the Brf1 signal. In 
contrast, the presence or absence of AREs did not affect the binding of other RNA 
binding proteins. For example, addition of an androgen receptor 3’UTR sequence, which 
contains a poly(C) RNA binding protein 1 (PCBP1) site, to Nanog mRNA permitted 
isolation of PCBP1 protein (Figure 4.2.C). This binding was not affected by the presence 
or absence of Nanog’s AREs. In contrast, a Nanog mRNA containing only a 120 
nucleotide polyA without a PCBP1 site did not bind PCBP1 protein. Together, these 
results confirm that Brf1 binds specifically to Nanog mRNA in an ARE-dependent 
manner. 
Regulation of these mRNA targets indicates that changes in Brf1 expression have 
the potential to broadly affect the pluripotency transcription factor network to influence 
the biology and behavior of mESCs.  
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Tables 
 
 
 
 
 
 
 
Motif % of Annotation Consensus 
-ATTTATTTATTTATTTATTTA- 0.08% Full 
-ATTTATTTATTTATTTA- 0.2% Full 
-ATTTATTTATTTA- 0.5% Full 
-ATTTATTTA- 4.5% Full 
-TTATTTATT- 6.0% Full (minimal) 
-TATTTAT- 22.8% Partial (minimal) 
-CTATTTATT- 2.2% Partial 
-TTATTTATC- 1.0% Partial 
-CTATTTATC- 0.5% Partial 
 
Table 4.1 – Frequency of ARE motifs among mouse protein coding genes.   
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Figures 
 
 
Figure 4.1 – Brf1 binds other pluripotency-associated mRNAs. (A) Method used for 
RNA-RBP immunoprecipitation and RNA sequencing (RIPseq). Sequencing statistics for 
two total RNA samples, two Brf1/2 antibody RIP derived samples and two rabbit IgG RIP 
controls are presented. (B) Distribution of ERIP values for actively expressed genes (n = 
7,194 genes). The location of several notable pluripotency associated transcripts is 
highlighted. Box Plot Statistics: median (red line, ERIP = 0.17), lower quartile boundary 
(ERIP = -0.04), upper quartile boundary (ERIP = 0.47) and statistical outliers (median ± 
1.5 × [upper quartile – lower quartile]). Table: Frequency of full ARE motifs (-
UUAUUUAUU-) and partial ARE motifs (-UAUUUAU-) among genes classified as ERIP 
outliers or in different ERIP quartiles.  
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Figure 4.2 – Nanog is bound and regulated by Brf1.  (A) Cartoon illustration of IL-2 and 
Nanog mRNA indicating the relative location and sequence of AU-rich elements in the 
3’UTR. ARE mutants were generated by changing the core (-ATTTA-) motif to (-AGGGA-). 
(B) Left: Schematic diagram of the assay used to extract RBPs from crude protein 
extracts. Beads are conjugated to mRNAs with or without AU-rich elements. Right: 
Western blot for Brf1 protein, present in IL-2 and Nanog mRNA protein isolates. ARE site 
mutations reduced the extraction of Brf1 from crude protein lysates for both IL-2 
sequence control and Nanog mRNA. (C) A Western blot for poly(C) RNA binding protein 
1 (PCBP1) was performed as an RBP recovery control. We appended a 3’UTR sequence 
from the androgen receptor (AR) gene which is known to bind PCBP1 (site underlined) 
to the 3’ end of wild-type and ARE mutant versions of Nanog (cartoon, top). We show 
that the presence or absence of ARE sequences does not inhibit the binding of PCBP1 to 
its target sequence. Moreover, the absence of the AR derived 3’UTR sequence prevents 
association with PCBP1 (as assayed using a polyA sequence of 120 nucleotides). 
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Chapter 5  
Brf1 post-transcriptionally regulates Nanog in response to FGF/Erk MAP kinase. 
(This chapter was adapted, in part, from (57)) 
Introduction 
We showed that FGF/Erk MAP kinase signaling strongly regulates the expression 
of Brf1, and that Brf1 binds Nanog mRNA in vitro. However, it remains unclear whether 
FGF signaling uses Brf1 to regulate Nanog mRNA expression. Although we have shown 
that post-transcriptional regulation of Nanog mRNA is ARE dependent, FGF could 
regulate Nanog mRNA stability through other uncharacterized AUBPs. To test whether 
Brf1 mediates FGF/Erk MAP kinase signaling-dependent regulation, we conducted an 
epistasis assay. 
Materials and Methods 
Mock or Brf1 siRNAs were transfected into fgf4-/- R1 mESCs. After 36 hours, 
changes in Brf1 or Nanog mRNA level, in the presence or absence of FGF4/Heparin, 
were measured using qRT-PCR. 
Results and Discussion 
Relative to siRNA control (Figure 5.1, first column), Brf1 siRNAs caused a slight 
(10%) downregulation of Brf1 and a corresponding increase in Nanog mRNA levels in 
fgf4-/- R1 mESCs (Figure 5.1, second column). These data indicate that Brf1 is expressed, 
albeit at a lower level, even when FGF signaling is absent (Figure 5.2) and that 
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alternative pathways support its basal expression. However, FGF signaling remains the 
dominant regulator of Erk MAP kinase in mESCs (Figure 5.2), and Erk MAP kinase 
appears to be the main driver of Brf1 expression (Figure 5.1).  
Addition of FGF4/Heparin ligand increased Brf1 and decreased Nanog by greater 
than 2-fold within 5 hours (Figure 5.1, third column). In agreement with its role as a 
regulatory intermediate, the presence of Brf1 siRNAs reduced this regulation, yielding a 
smaller upregulation of Brf1 and a smaller downregulation of Nanog (Figure 5.1). We 
note that the inability of Brf1 siRNAs to fully block the downregulation of Nanog can be 
partly explained by limited knockdown efficiency, but could also reflect Brf1-
independent regulatory mechanisms. In the absence of a more stringent test of epistasis 
(i.e. zfp36l1-/- mESCs), these data are sufficient to demonstrate Brf1’s role as a 
regulatory intermediate of the FGF signaling pathway. 
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Figure 5.1 – Brf1 regulates Nanog in response to FGF.  Transfection of Brf1 siRNAs can 
compromise the regulation of Nanog by FGF4/Heparin in fgf4-/- mESCs [ SD, n = 2]. 
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Figure 5.2 – Brf1 is strongly regulated by FGF/Erk MAP kinase signaling. Shown are 
relative differences in Brf1 expression level among different cell types and cell culture 
conditions, as specified.  
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Chapter 6  
Changes in Brf1 expression affect mouse ESC self-renewal and developmental 
potential. 
(This chapter was adapted, in part, from (57)) 
Introduction 
FGF/Erk MAP kinase signaling destabilizes the expression of pluripotency factors, 
and is required for mESC differentiation. Our RIPseq data connects Brf1 to the 
regulation of numerous pluripotency factors. As a mediator of FGF/Erk MAP kinase 
signaling, changes in Brf1 expression may strongly regulate self-renewal, pluripotency or 
differentiation responses.  
Materials and Methods 
To determine the functional effect of Brf1 expression on pluripotent and 
differentiating cells, we perturbed Brf1 expression using siRNAs, which produced a 4-
fold decrease in Brf1 protein relative to wild-type. We also created stable transgene-
mediated overexpression cell lines, which increased Brf1 protein levels 4-fold above 
wild-type levels (Figure 6.1.A). For transgene expression in mESCs, clones expressing 
H2B-YFP (Brf11x) or Brf1-T2A-H2B-YFP (Brf14x) were derived for these studies. Of these, 
one control Brf11x clone that expressed wild-type levels of Brf1 protein, and one Brf14x 
clone expressing 4-fold more Brf1 protein, was chosen for further analysis.  
Results and Discussion 
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To quantify changes in mESC self-renewal brought about by Brf1 overexpression, 
we co-cultured YFP(+) Brf14x clones with wild-type YFP(-) E14 mESCs. In this assay, any 
change in self-renewal ability manifests as changes in relative proliferation rate, and 
hence, a change in the YFP(+)/YFP(-) ratio (91). Compared to Brf11x, co-cultures with 
Brf14x exhibited a significant proliferation defect, with the YFP(+)/YFP(-) ratio reduced by 
20% every 48 hours (Figure 6.1.B). In these cells, the expression of several core 
pluripotency genes is altered (Figure 6.1.C). However, most remain pluripotent in 
conditions with LIF plus serum. Removing LIF rapidly initiates differentiation, and during 
the first 48 hours, Brf1 siRNA knockdown in Brf11x or Brf1 overexpression in Brf14x 
produced only modest effects on the rate at which some markers of pluripotency were 
downregulated (Figure 6.1.D). 
In contrast to the mild effect of Brf1 expression on the downregulation of 
pluripotency factors (Figure 6.1.D), the upregulation of differentiation markers is 
strongly affected by Brf1 (Figure 6.2). After 3 days of LIF withdrawal, we observed a 
striking bias in gene expression when comparing Brf14x to Brf11x cultures. LIF withdrawal 
generally promotes mesoderm differentiation (92). Indeed, Brachyury (T) was 
upregulated in differentiating Brf11x and Brf14x cultures. However, Brachyury expression 
was 100-fold greater in the Brf14x cell line (Figure 6.3.A). Transfecting Brf11x cultures 
with Brf1 siRNAs produced the opposite effect, downregulating Brachyury expression 
approximately 4-fold relative to untreated controls (Figure 6.3.A). Furthermore, siRNAs 
against Brf1 could attenuate the upregulation of Brachyury in Brf14x, indicating that this 
regulation resulted specifically from Brf1 overexpression. In agreement with these 
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results, flow cytometry profiling indicated that a larger fraction of Brf14x cells expressed 
Brachyury protein by 84 hours compared to Brf11x (Figure 6.3.C). These findings were 
further supported by the upregulation of mesendodermal markers Goosecoid (Gsc), 
Mixl1, and Wnt3A (Figure 6.3.A), indicating that Brf1 accelerated commitment to 
mesendodermal fates. Ectoderm markers (Nodal, Fgf5 and Gbx) were not affected, 
whereas extra-embryonic and definitive endoderm markers (Gata6, Hnf4a and FoxA2) 
showed weaker basal expression levels that responded differentially to Brf1 (Figure 
6.3.A).   
Brf1 expression did not influence neural differentiation. Because serum inhibits 
neural differentiation (32), we cultured cells in N2B27 serum-free media without LIF and 
BMP4. After 3 days in this media, most markers of differentiation appeared to be 
unaffected by Brf1 (Figure 6.3.B). For example, Sox1 mRNA and protein was readily 
detected, but its expression levels were similar in Brf11x and Brf14x cultures (Figure 6.3.B 
and 6.3.C). Interestingly, even in N2B27, the basal expression of Brachyury was 
upregulated in a Brf1-dependent manner. Thus, Brf1 appears to mainly affect 
mesendodermal differentiation pathways. 
 
  
61 
 
Figures 
 
 
Figure 6.1 – Brf1 expression compromises mouse ESC self-renewal. (A) Brf1 expression 
was profiled in E14 carrying a CMV-H2B-YFP expression cassette (Brf1
1x
), Brf1
1x
 treated 
with Brf1 siRNAs, and E14 carrying a CMV-Brf1/T2A/H2B-YFP expression cassette 
(Brf1
4x
). A Western blot of Brf1 protein shows that siRNA knockdown reduced Brf1 
expression by 75% after 36 hours, and stable CMV driven Brf1 expression increases Brf1 
protein levels by 4-fold relative to Brf1
1x
. Chemiluminscent intensities were normalized 
to Gapdh signal as loading control. (C) Changes in self-renewal of Brf1
4x
 relative to 
Brf1
1x
. Differences in proliferation rate were gauged by changes in the ratio of YFP(+) 
transgene expressing cells to YFP(-) wild-type cells. For t = 48 and 96 hours [ SEM, n = 
4]. For t = 120 and 144 hours [ SEM, n = 3]. (D) Changes in the expression of core 
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pluripotency genes via RT-qPCR after Brf1 siRNA knockdown in Brf1
1x
 (gray bars) or 
enhanced Brf1 expression in Brf1
4x
 (blue bars) over 36 hours [ SEM, n = 2]. (F) Profiling 
changes in the expression of core pluripotency genes via RT-qPCR during the early 
stages of differentiation (15% Serum, without LIF) in Brf1
1x
 treated with Brf1 siRNAs 
(dashed black line), Brf1
1x
 (solid black line) and Brf1
4x
 (solid blue line) [ SEM, n = 2]. 
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Figure 6.2 – Developmental potential of mouse ESCs. 
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Figure 6.3 – Brf1 expression promotes mesendoderm differentiation. (A) Brf11x and 
Brf14x were cultured in mesoderm differentiation media (15% Serum without LIF) for 3 
days. Fold difference in the expression of several lineage specific differentiation markers 
in Brf14x relative to Brf11x after 3 days of differentiation [ SEM, n = 3]. (B) Brf11x and 
Brf14x were cultured in neuroectoderm differentiation media (N2B27) for 3 days. Fold 
difference in the expression of several lineage specific differentiation markers in CMV-
Brf1 E14 relative to Control E14 after 3 days of differentiation [ SEM, n = 3]. (C) (Right) 
Brachyury immunostain and associated flow cytometry data after 3.5 days of 
differentiation (n = 2000 cells). (Left) Sox1 immunostain and associated flow cytometry 
data after 5 days of differentiation (n = 1500 cells). 
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Concluding Remarks 
AUBPs are critical regulators of developmental gene expression which respond 
to inter- and intracellular signals. Some specific examples of this regulation include the 
repression of Notch1 in response to PI3K/Erk MAP kinase signals during T-cell 
development (93), repression of TNFalpha in response to p38/Erk MAP kinase signals 
during inflammation (94), and the stabilization of p21 in response to ATR/ATM kinase 
activation after DNA damage (95). Here we demonstrate AUBPs mechanistically connect 
FGF/Erk MAP kinase signaling to the regulation of pluripotency, self-renewal and 
differentiation in mESCs. More specifically, control over Brf1 expression rapidly 
regulates the expression of key pluripotency-associated genes, reduces the capacity to 
self-renew, and enhances mesendoderm differentiation upon LIF withdrawal.  
Why has Brf1 been selected for implementing FGF-dependent cellular responses 
in mESCs? One possibility is that, owing to its rapid transcriptional response to FGF 
signaling and its short protein and mRNA half-life (1.5 hours and 1 hour, respectively), 
Brf1 is capable of tracking dynamic changes in Erk MAP kinase activity. Brf1 directly 
affects mRNA abundance, and provides stem cell populations with a mechanism to 
quickly respond to changes in FGF signaling, without necessarily altering underlying 
transcriptional states. However, the benefit of these dynamical properties to the biology 
of pluripotent or differentiating mESCs still remains unclear. Brf1 also provides a 
regulation that is similar to miRNAs, which also provide mRNA-level repression while 
maintaining flexibility in target selection. Interestingly, Zfp36 AUBPs and miRNAs are 
known to cooperate in regulating some mRNA targets (96), indicating a potential point 
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of convergence between these two regulatory mechanisms. Future work will address 
why this system is particularly well adapted to serve as a regulator in mESCs, and as a 
mediator of FGF/Erk MAP kinase signaling.  
Whether Brf1 plays a similar role in the embryo is unclear. We note that the 
regulatory effects of Brf1 in cell culture mimic the developmental response to FGF/Erk 
MAP kinase signaling at different stages of embryonic development. For example, FGF4 
signaling promotes extra-embryonic endoderm differentiation in the inner cell mass 
partly by destabilizing the expression of pluripotency genes (97). Brf1 may participate in 
this process by repressing Nanog and other pluripotency regulators. At a slightly later 
developmental stage, and one that is more relevant to mESCs, both FGF4 and FGF8 are 
required for mesoderm induction (98, 99). The expression of Brachyury, a regulator of 
mesoderm morphogenesis, is enhanced by FGF4 and FGF8 signaling through unknown 
mechanisms (100). Our results show that Brf1 expression during differentiation in 
mESCs similarly enhances Brachyury and other primitive streak markers. This regulatory 
connection could explain why Brf1 knockout mice also exhibit the same gross defects in 
chorio-allantoic fusion, neural tube closure and placental organization at mid-gestation 
(E11) as FGFR2 knockouts, an indication of shared regulation and function (74, 101). 
Although the regulation of FGF/Erk MAP kinase signaling likely differs between the 
embryonic and cell culture context, these observations implicate Brf1 as an important 
FGF/Erk MAP kinase-inducible regulator of development in both systems. 
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Appendix A 
Supplemental Materials and Methods 
Cell Lines and Cell Culture 
fgf4-/- mESCs (strain FD6) were a kind gift ofrom Dr. Angie Rizzino, University of 
Nebraska Medical Center.  
 
Cultures were routinely passaged in complete ES culture medium (15% FBS, 1000U/ml 
LIF, NEAA, Sodium Pyruvate and ME in DMEM) in the absence of feeders. Mesoderm 
differentiation media: 15% FBS, NEAA, Sodium Pyruvate and ME in DMEM (92); 
Neurectodermal differentiation media: N2B27 serum free media (102).  
Reagents, Antibodies, Signaling Inhibitors and siRNAs 
Qiazol reagent (Qiagen); iScript Kit (Bio-Rad); SsoFast Probes Supermix (Bio-Rad) 
 
Mouse monoclonal (L34F12) anti-p44/p42 (Cell Signal, Cat# 4696, 1:2000); Rabbit 
monoclonal (D13.14.4E) anti-phospho-p44/p42 (Cell Signal, Cat# 4370, 1:2000); Mouse 
anti-TBP (Abcam, Cat# ab818, 1:1000); Rabbit anti-Beta Tubulin (Abcam, Cat# ab6046, 
1:1000); Rabbit polyclonal anti-Brf1/2 (Cell Signal, Cat# 2119, 1:1000); Rabbit anti-Zfp36 
(Protein Tech Group, Cat# 12737-1-AP, 1:500); Rabbit anti-hnRNP E1 (Cell Signal, Cat# 
8534, 1:500); Goat anti-Brachyury (R & D Systems, Cat# AF2085, 1:200); Rabbit anti-Sox1 
(GeneTex, Cat# GTX62974, 1:200); Mouse anti-Gapdh (Abcam, Cat# ab8245, 1:5000) 
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CI-1040 (also known as PD184352, Axon, 5uM); PD173074 (Sigma, 100ng/ml) 
 
TTP siRNA (Santa Cruz Biotechnology, 10nM); Brf1 siRNA (Santa Cruz Biotechnology, 
10nM); Brf2 siRNA (Santa Cruz Biotechnology, 10nM); All Stars Negative Control siRNA 
(Qiagen, 10nM) 
High Throughput Sequencing Data 
Raw sequencing data discussed in this publication was deposited in the NCBI Gene 
Expression Omnibus (Accession Number: GSE40104). 
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Appendix B 
Supplemental Information 
Primers and Probe Characterization: 
Gene Name Accession Primers and Probe Slope/Efficiency/R
2
 
Citrine (YFP)  Primer1: 5’-CCACCTTCGGCTACGGCCTGA-3’ 
Primer2: 5’-GCCATGATATAGACGTTGTGG-3’ 
3.24/116%/0.998 
Dab2 NM_023118.5 Primer1: 5’-TGTACTTTGTGGGTTCTGTCC-3’ 
Primer2: 5’-GGTTGTGCTTGTTTCTACTTCG-3’ 
Probe: 5’-CTGCTTGCCTTCCCGTCATGTCTAA-3’ 
3.59/90%/0.999 
Esrr NM_011934.4 Primer1: 5’-CCTTTACTATCTGTGCCTGGTC-3’ 
Primer2: 5’-AGTGCTTCTCTTTGGTGCTG-3’ 
Probe: 5’-ACACGTCTGTCATCCTTGCCTGC-3’ 
3.27/102%/0.998 
Fgf5 NM_010203.4 Primer1: 5’-TGACTGGAATGAGTGCATCTG-3’ 
Primer2: 5’-GGGTTTGGAATTTGGGTTGAG-3’ 
Probe: 5’-ATTAAGCTCCTGGGTCGCAAGGG-3’ 
3.40/97%/1.000 
FoxA2 NM_010446.2 Primer1: 5’-GATGTACGAGTAGGGAGGTTTG-3’ 
Primer2: 5’-AACATGAACTCGATGAGCCC-3’ 
Probe: 5’-CCAAGACATACCGACGCAGCTACA-3’ 
3.21/105%/0.999 
Gapdh NM_008084.2 Primer1: 5’-CTCCACGACATACTCAGCAC-3’ 
Primer2: 5’-CCACTCACGGCAAATTCAAC-3’ 
Probe: 5’-AGGAGCGAGACCCCACTAACATCA-3’ 
3.38/97%/0.999 
Gata6 NM_010258.3 Primer1: 5’-AGCAAGATGAATGGCCTCAG-3’ 
Primer2: 5’-CTCACCCTCAGCATTTCTACG-3’ 
Probe: 5’-CAACTGTCACACCACAACCACTACCT-3’ 
3.35/99%/1.000 
Gbx2 NM_010262.3 Primer1: 5’-GCAGTGTTTTGAAAGGGATAGG-3’ 
Primer2: 5’-TGTTTGTCCTTGTGTCTCCTG-3’ 
Probe: 5’-TTTGGGCACGTATGGGAAGGTGG-3’ 
3.63/89%/0.999 
Hnf4 NM_008261.2 Primer1: 5’-GGGCAGGAGAAGGATAAGAAAG-3’ 
Primer2: 5’-GCAAAGCCATCAAGAGTCAAC-3’ 
Probe: 5’-TGGGAAGCTACAGTCAAGGTGCATT-3’ 
3.68/87%/0.996 
Hprt NM_013556.2 Primer1: 5’-GCCCCAAAATGGTTAAGGTTG-3’ 
Primer2: 5’-AACAAAGTCTGGCCTGTATCC-3’ 
Probe: 5’-CTTGCTGGTGAAAAGGACCTCTCGAA-3’ 
3.36/98%/0.999 
Nanog NM_028016.2 Primer1: 5’-CAAAGGATGAAGTGCAAGCG-3’ 
Primer2: 5’-CCAGATGCGTTCACCAGATAG-3’ 
Probe: 5’-CAGCACCAGTGGAGTATCCCAGC-3’ 
3.35/99%/0.999 
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Nodal NM_013611.4 Primer1: 5’-TTCACCGTCATTCCTTCTCAG-3’ 
Primer2: 5’-GATGCCAACACTTTTCTGCTC-3’ 
Probe: 5’-ACACCTGCTTTTCCAGTGCCCT-3’ 
3.38/98%/1.000 
Oct4 NM_013633.3 Primer1: 5’-CACTCTACTCAGTCCCTTTTCC-3’ 
Primer2: 5’-GTTCTCTTGTCTACCTCCCTTG-3’ 
Probe: 5’-TTTCCCTCTGTTCCCGTCACTGC-3’ 
3.34/99%/1.000 
Rex1 NM_009556.3 Primer1: 5’-ACATCCTAACCCACGCAAAG-3’ 
Primer2: 5’-CATTAAGACTACCCAGCCTGAG-3’ 
Probe: 5’-TGTCTCCACCTTCAGCATTTCTTCCC-3’ 
3.17/107%/1.000 
Sdha NM_023281.1 Primer1: 5’-AGTGGGCTGTCTTCCTTAAC-3’ 
Primer2: 5’-GGATTGCTTCTGTTTGCTTGG-3’ 
Probe: 5’-TGGGCATGTCTCTGAGGGATTGG-3’ 
3.21/105%/1.000 
Sox1 NM_009233.3 Primer1: 5’-TCTTTCCTGTGGTTCTGCC-3’ 
Primer2: 5’-GAAATCAAAGGCACGCTGTC-3’ 
Probe: 5’-TTGTCCCTATCCTTGGCCTTGTCC-3’ 
3.79/84%/0.999 
Sox2 NM_011443.3 Primer1: 5’-CCAATCCCATCCAAATTAACGC-3’ 
Primer2: 5’-CTATACATGGTCCGATTCCCC-3’ 
Probe: 5’-CCGCCCTCAGGTTTTCTCTGTACAA-3’ 
3.78/84%/0.999 
T NM_009309.2 Primer1: 5’-GCTGGAAATATGTGAACGGG-3’ 
Primer2: 5’-GTTGGTGAGTTTGACTTTGCTG-3’ 
Probe: 5’-AAAATTGGGCGAGTCTGGGTGGA-3’ 
3.87/81%/1.000 
Tbp NM_013684.3 Primer1: 5’-TGATTGCTGTACTGAGGCTG-3’ 
Primer2: 5’-CTTACGGCACAGGACTTACTC-3’ 
Probe: 5’-ACTGTTGGTGTTCTGAATAGGCTGTGG-3’ 
3.24/104%/0.998 
Tbx3 NM_011535.2 Primer1: 5’-TCCCATTATCCTCAACCTTGC-3’ 
Primer2: 5’-CACACGAAGCCCTCTACAAG-3’ 
Probe: 5’-CCATAGCTGCCCCTTTTACCCCA-3’ 
3.48/94%/0.998 
Zfp36 (TTP) NM_011756.4 Primer1: 5’-CCCTGTCCTCTTGTTCCTTTTC-3’ 
Primer2: 5’-TGGTTAGGGTCTCTTCGAGTC-3’ 
Probe: 5’-CTTTCCCCTTCTGCCTTCTCTGCT-3’ 
3.14/108%/1.000 
Zfp36l1 
(Brf1) 
NM_007564.5 Primer1: 5’-GCACACTCTTCCTCTTCCTTATAG-3’ 
Primer2: 5’-AGGCAAGATTAGTCAACAGGG-3’ 
Probe: 5’-ACCTTTTACTTCCCAGCCCGAACC-3’ 
3.23/104%/0.997 
Zfp36l2 
(Brf2) 
NM_001001806.2 Primer1: 5’-TCGCCCGTTATTCATCTTGG-3’ 
Primer2: 5’-CGTAGAAGGGTGACAGAAGTG-3’ 
Probe: 5’-AAGCGTGGAGGTTGGGAGGT-3’ 
3.17/107%/1.000 
½ life tag  Primer1: 5’- CTGTTTTGACCTCCATAGAAGAC-3’ 
Primer2: 5’- AGATTGAGGATGCTGAGCGTC-3’ 
3.32/100%/0.999 
 
